Home — Centre for Immuno-Oncology

The Center for Immuno-Oncology (CIO) investigates how our immune system reacts to cancer and what we can do to improve tumour immunity. We combine deep fundmental understanding of immunology with preclinical studies to translate new knowledge into clinical trials with the aim of developing new life-saving treatments for a spectrum of cancers.

Oxford’s long history of excellence in immunology is now focused on cancer, and CIO is the hub of the University-wide Oxford Cancer Immuno-Oncology Network (OCION) which links immuno-oncology researchers from multiple disciplines from across the University of Oxford, its affiliated hospitals and industrial partners.

About Centre for Immuno-Oncology Research

Work with us

Against Breast Cancer appoint new Oriel College Research Fellow

4 August 2026

Against Breast Cancer (ABC) have welcomed Dr Isabela Pedroza-Pacheco as their newest Junior Research Fellow at Oriel College, University of Oxford. Dr Pedroza is a Career Development Fellow at the Nuffield Department of Medicine, with an established record in vaccine and immunology research.

Centre for Immuno-Oncology Away Day 2026

4 August 2026

Colleagues from across the Centre for Immuno-Oncology (CIO) gathered to celebrate and reflect on the impact of their collective research with a full programme of talks, posters and career discussions.

Michael Bryan named BNOS Young Investigator of the Year 2026

30 July 2026

Huge congratulations to Michael E. Bryan, who has been named British Neuro-Oncology Society Young Investigator of the Year 2026.

Oxford team recognised by Royal College of Physicians for pioneering AI cancer vaccine research

29 July 2026

Research led from Oxford has been recognised by the Royal College of Physicians at its Excellence in Patient Care Awards 2026, celebrating pioneering work to accelerate the development of personalised cancer vaccines using artificial intelligence and advanced computing.

Oxford Cancer News

World Cancer Day

Discover how our researchers are tackling the major challenges in Cancer Research 🔬🧬 👉Featuring here Dr.Pedroza-Pacheco, Dr. Galvez-Cancino and and Dr.Leung from our Centre for immuno-Oncology 🎥 Watch the video to see the breakthroughs we're striving for! #Innovation

United by unique

This year’s #WorldCancerDay theme is 'United by Unique' and our work at the Centre for immuno-Oncology aligns with it by using fundamental science and exploring environmental factors to develop innovative personalised therapies

The future of Cancer Resarch

At the centre for immuno-Oncology we are focusing on improving patient outcomes through personalized approaches Watch the video to see how we’re transforming the future for cancer patients. 🎥 #CancerWorldDay

Latest publications

DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8 + T cell responses and therapeutic protection in mouse tumor models.

Morgado-Cáceres P. et al, (2026), Oncoimmunology, 15

Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies.

Sweis RF. et al, (2026), Journal for immunotherapy of cancer, 14

A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1-LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma.

Garralda E. et al, (2026), Clinical cancer research : an official journal of the American Association for Cancer Research, 32, 2556 - 2571

The Airway Transcriptome in Type 2 Cytokine Biomarker-High and -Low Severe Asthma.

Shen J. et al, (2026), Allergy

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Melero I. et al, (2026), Journal of hematology & oncology

Genetic characterization of the TAPBP and its allelic association with BF2 in the chicken major histocompatibility complex.

Fernando R. et al, (2026), Immunogenetics, 78

An HIV-1 gp41 MPER liposome vaccine elicits neutralizing epitope-targeted antibody responses in HIV-seronegative individuals

Erdmann N. et al, (2026), Nature Communications

Association Between Chronic Inflammation, Bone Density, and Muscle in Peripubertal Adolescents With and Without HIV in Zimbabwe: A Cross-sectional Study.

Jeena L. et al, (2026), Open forum infectious diseases, 13

Engineering and improving anti-CTLA-4 checkpoint inhibitors.

Galvez-Cancino F. et al, (2026), Clinical cancer research : an official journal of the American Association for Cancer Research

Ensuring vaccine cold chain integrity: A rapid and low-cost test for identifying heat-exposed sucrose-containing vaccines.

Arman BY. et al, (2026), International journal of pharmaceutics: X, 11

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

Rohrberg KS. et al, (2026), Journal for immunotherapy of cancer, 14

Association of Diabetes Mellitus With a Shared Hyperinflammatory Immune Response in Patients With Melioidosis and Patients With Tuberculosis: An Observational Case-Control Study.

Rongkard P. et al, (2026), Open forum infectious diseases, 13

About Centre for Immuno-Oncology Research

Work with us

CIO News

Against Breast Cancer appoint new Oriel College Research Fellow

Centre for Immuno-Oncology Away Day 2026

Michael Bryan named BNOS Young Investigator of the Year 2026